Last reviewed 2026-04-23 · How we verify

batch 2 of MCV4

CanSino Biologics Inc. · Phase 3 active Biologic

batch 2 of MCV4 is a Conjugate vaccine Biologic drug developed by CanSino Biologics Inc.. It is currently in Phase 3 development for Active immunization against invasive disease caused by Neisseria meningitidis serogroups A, C, W, and Y. Also known as: Menhycia.

MCV4 is a vaccine that stimulates the body's immune response to the meningococcal conjugate serogroups A, C, W, and Y.

MCV4 is a vaccine that stimulates the body's immune response to the meningococcal conjugate serogroups A, C, W, and Y. Used for Active immunization against invasive disease caused by Neisseria meningitidis serogroups A, C, W, and Y.

At a glance

Generic name	batch 2 of MCV4
Also known as	Menhycia
Sponsor	CanSino Biologics Inc.
Drug class	Conjugate vaccine
Modality	Biologic
Therapeutic area	Infectious Disease
Phase	Phase 3

Mechanism of action

MCV4 works by introducing a small, harmless piece of the meningococcal bacteria to the body, which triggers an immune response and helps the body produce antibodies to fight the infection. This immune response provides long-term protection against meningococcal disease. The vaccine is typically administered as a single dose or a booster dose to individuals who have previously received the vaccine.

Approved indications

Active immunization against invasive disease caused by Neisseria meningitidis serogroups A, C, W, and Y

Common side effects

Pain, redness, swelling, or itching at the injection site
Fatigue
Headache

Key clinical trials

A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

batch 2 of MCV4 CI brief — competitive landscape report
batch 2 of MCV4 updates RSS · CI watch RSS
CanSino Biologics Inc. portfolio CI

Frequently asked questions about batch 2 of MCV4

What is batch 2 of MCV4?

batch 2 of MCV4 is a Conjugate vaccine drug developed by CanSino Biologics Inc., indicated for Active immunization against invasive disease caused by Neisseria meningitidis serogroups A, C, W, and Y.

How does batch 2 of MCV4 work?

MCV4 is a vaccine that stimulates the body's immune response to the meningococcal conjugate serogroups A, C, W, and Y.

What is batch 2 of MCV4 used for?

batch 2 of MCV4 is indicated for Active immunization against invasive disease caused by Neisseria meningitidis serogroups A, C, W, and Y.

Who makes batch 2 of MCV4?

batch 2 of MCV4 is developed by CanSino Biologics Inc. (see full CanSino Biologics Inc. pipeline at /company/cansino-biologics-inc).

Is batch 2 of MCV4 also known as anything else?

batch 2 of MCV4 is also known as Menhycia.

What drug class is batch 2 of MCV4 in?

batch 2 of MCV4 belongs to the Conjugate vaccine class. See all Conjugate vaccine drugs at /class/conjugate-vaccine.

What development phase is batch 2 of MCV4 in?

batch 2 of MCV4 is in Phase 3.

What are the side effects of batch 2 of MCV4?

Common side effects of batch 2 of MCV4 include Pain, redness, swelling, or itching at the injection site, Fatigue, Headache.

Drug class: All Conjugate vaccine drugs
Manufacturer: CanSino Biologics Inc. — full pipeline
Therapeutic area: All drugs in Infectious Disease
Indication: Drugs for Active immunization against invasive disease caused by Neisseria meningitidis serogroups A, C, W, and Y
Also known as: Menhycia
Compare: batch 2 of MCV4 vs similar drugs
Pricing: batch 2 of MCV4 cost, discount & access